CORRECT: Sareum notes US FDA approval of Bristol-Myers's Sotyktu

(Correcting that Bristol-Myers gained US FDA approval, not Sareum.) (Alliance News) - Sareum ...

Alliance News 13 September, 2022 | 7:13AM
Email Form Facebook Twitter LinkedIn RSS

(Correcting that Bristol-Myers gained US FDA approval, not Sareum.)

(Alliance News) - Sareum Holdings PLC on Monday noted that the US Food & Drug Administration has approved Bristol-Myers Squibb Co's Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor.

Sareum is a Cambridge, England-based drug developer for cancer and autoimmune diseases.

The company said that Sotyktu is for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

The US FDA approval is based on a pivotal Phase 3 study of deucravacitinib which demonstrated "superior efficacy" against placebo and standard of care. Deucravacitinib was "well tolerated" in the Phase 3 study, Sareum added.

The company said that the approval provides clinical validation for the broader TYK2/JAK1 signalling family, which underpins its clinical portfolio.

Chief Executive Tim Mitchell said: "We're encouraged that the FDA has approved Sotyktu. We believe this validates the potential of this new therapeutic class and supports our own growing confidence around our lead programme and our broader portfolio of TYK2/JAK1 inhibitors."

By Sophie Rose; sophierose@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Sareum Holdings PLC 26.25 GBX 0.00 -
Bristol-Myers Squibb Co 44.85 USD 0.34

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures